Understanding Hemophilia A and B Drug Dosage Administration Patterns
UNDERSTANDING HEMOPHILIA A AND B DRUG DOSAGE ADMINISTRATION PATTERNS
Study Design A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings. 30 sites will enroll approximately 300 patients Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate. Physicians complete a retrospective chart review on each enrolled patient. Patients will complete a one-time study questionnaire.
Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. Subjects currently enrolled into the study have completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment.
Resource Utilization Pattern
Hemophilia B standard half-life
Study Arms / Comparison Groups
Description: real world administration patterns and resource utilization implications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
September 1, 2017
March 14, 2018
Primary Completion Date
March 14, 2018
Physician/Clinician Participants: - Must be a healthcare provider - Currently manages at least 10 hemophilia A and/or B patients Patient Participants: - Willing and able to provide informed consent - Diagnosed with hemophilia A or B - Current disease severity is either moderately severe or severe with a clotting factor level of ≤5% - If suffering from hemophilia A, must be currently taking moroctocog alfa (or another standard half-life treatment), rurioctocog alfa or efraloctocog alfa for at least six months. (If currently taking rurioctocog alfa or efraloctocog alfa, must have been switched from a standard half-life treatment and had been on that prior treatment for at least six months). - If suffering from hemophilia B, must be currently taking nonacog alfa or eftrenonacog alfa for at least six months (If currently taking eftrenonacog alfa, must have switched from nonacog alfa and had been on that prior treatment for at least six months). - Infuse at least 3 times per month Exclusion criteria: - Female with hemophilia A or B - Mild Haemophilia A or B
N/A - N/A
Accepts Healthy Volunteers
Pfizer CT.gov Call Center, ,
Pfizer CT.gov Call Center, Study Director, Pfizer